From Near-Infrared to Multiplex Detection: Technological Advances and Industry Trends in Biofluorescence Reagents

Development of Near-Infrared Fluorescence and Low-Background Detection

The spectral range of biofluorescent reagents continues to expand into the near-infrared region. Near-infrared fluorophores generally exhibit lower tissue autofluorescence and greater tissue penetration depth, demonstrating clear advantages in in vivo imaging, in vitro diagnostics, and multiplex immunohistochemistry. Compared with visible-light dyes, near-infrared dyes have longer emission wavelengths, which can reduce background interference from endogenous substances in biological samples and improve the signal-to-noise ratio. For example, in immunochromatography and fluorescence quantitative detection, near-infrared labeling can reduce interference from sample color or impurities. However, the quantum yield and photostability of near-infrared fluorescent reagents may vary across different solvents, and selection should take into account the detector sensitivity and filter configuration of the detection instrument. As detection platforms increasingly support near-infrared channels, the application scope of such biofluorescent reagents is gradually expanding.

Multiplex Labeling and Spectral Unmixing Technologies

Multiplex immunohistochemistry and multiparameter flow analysis impose higher requirements on biofluorescent reagents. Traditional fluorophores have broad emission spectra and are prone to cross-talk during multiplex labeling. In recent years, the development of nanomaterials with narrow emission spectra and spectral unmixing algorithms has provided better tools for multiplex labeling. Quantum dots, polymer dots, and rare-earth nanophosphors possess tunable emission peaks and narrow full width at half maximum, facilitating simultaneous detection of multiple targets in a single experiment. Spectral flow cytometers can acquire full-spectrum information and resolve the contributions of different fluorophores through mathematical unmixing, thereby reducing dependence on filter combinations. In multiplex labeling experiments, appropriate single-stain controls and fluorescence compensation must still be set up to ensure the reliability of unmixing results. The combinatorial design of biofluorescent reagents should take into account the abundance and spatial distribution of each target to avoid excessive differences in signal intensity that could compromise quantification.

Fluorescence Lifetime Imaging and Novel Probe Technologies

In addition to fluorescence intensity, fluorescence lifetime, as a parameter less dependent on concentration and excitation light intensity, is receiving increasing attention. Fluorescence lifetime imaging technology measures the temporal decay characteristics of fluorophore excited states, enabling discrimination of fluorescent signals with similar spectra but different lifetimes, thereby enhancing detection specificity in complex samples. Some biofluorescent reagents are designed as activatable probes that respond to specific microenvironments or enzyme activities, fluorescing only when the target is present, thus reducing background. Such smart probes hold application potential in tumor marker detection, drug screening, and cell signaling pathway research. It should be noted that novel probes require thorough validation of stability, biocompatibility, and batch-to-batch consistency before transitioning from the laboratory to industrialization. For in vitro diagnostic applications, systematic analytical performance evaluation and preclinical studies must also be completed.

In Vitro Diagnostic Reagent Innovation and Industry Collaboration

In the field of in vitro diagnostics, biofluorescent reagents are often used as core raw materials in products such as immunoassays, molecular diagnostics, and flow cytometry. With the advancement of precision medicine and tiered diagnosis and treatment, demand for highly sensitive, multiplexed, and automated detection continues to grow. Upstream fluorescent reagent suppliers, midstream kit manufacturers, and downstream clinical testing institutions need to strengthen technical collaboration and quality control data sharing. The development of innovative products should be oriented around actual clinical needs, such as improving detection sensitivity for low-abundance markers, shortening detection time, and reducing sample consumption. At the same time, registration and market launch of new products must meet relevant regulatory requirements for analytical performance, stability, and clinical evaluation. Technical specifications and performance data generated during R&D should be authentic and traceable, and promotional materials should avoid exaggerating the scope of application or using non-compliant comparative statements.

Boundaries of Industry Standards and Science Communication

The biofluorescent reagent industry undergoes rapid technological updates, but science communication and marketing must adhere to objective and accurate principles. In the domestic market, promotional materials for in vitro diagnostic-related products and research reagents must not contain medical efficacy claims or use absolute terminology. When biofluorescent reagents are intended as research or production raw materials, their intended use scope should be clearly labeled to avoid misleading consumers into using them directly for clinical diagnosis or treatment. When introducing products, companies may cite publicly published research literature or technical validation data, but sources should be indicated, and detection data or clinical conclusions must not be fabricated. For products that have not yet obtained registration certificates, it should not be stated or implied that they can be used as in vitro diagnostic reagents for clinical testing. Industry organizations and enterprises should also jointly promote standardized terminology and performance evaluation methods to help users correctly understand the differences among various biofluorescent reagents and promote healthy industry development.

Overall, technological advances in biofluorescent reagents are moving toward near-infrared, multiplexed, smart-responsive, and high-throughput directions.The scientific research and industrial communities need to strike a balance between innovation and compliance, driving sustained progress in the life sciences and in vitro diagnostics industries with authentic and reliable performance data and application support.